Ocular Therapeutix, Inc.
OCUL
$7.45
-$0.49-6.17%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 63.72M | 61.44M | 61.10M | 59.84M | 58.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.72M | 61.44M | 61.10M | 59.84M | 58.44M |
| Cost of Revenue | 133.26M | 108.62M | 86.40M | 72.44M | 66.34M |
| Gross Profit | -69.54M | -47.18M | -25.31M | -12.59M | -7.89M |
| SG&A Expenses | 102.24M | 94.07M | 89.16M | 78.86M | 74.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 235.50M | 202.70M | 175.57M | 151.29M | 140.83M |
| Operating Income | -171.78M | -141.26M | -114.47M | -91.45M | -82.38M |
| Income Before Tax | -193.51M | -174.34M | -138.36M | -115.27M | -80.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -193.51 | -174.34 | -138.36 | -115.27 | -80.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -193.51M | -174.34M | -138.36M | -115.27M | -80.74M |
| EBIT | -171.78M | -141.26M | -114.47M | -91.45M | -82.38M |
| EBITDA | -167.99M | -137.46M | -110.75M | -88.03M | -79.40M |
| EPS Basic | -1.26 | -1.32 | -1.11 | -1.11 | -1.01 |
| Normalized Basic EPS | -0.66 | -0.69 | -0.67 | -0.67 | -0.74 |
| EPS Diluted | -1.26 | -1.32 | -1.35 | -1.36 | -1.26 |
| Normalized Diluted EPS | -0.66 | -0.69 | -0.66 | -0.66 | -0.73 |
| Average Basic Shares Outstanding | 632.86M | 549.27M | 461.65M | 373.87M | 319.24M |
| Average Diluted Shares Outstanding | 632.86M | 549.27M | 467.42M | 379.64M | 325.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
